ArticleBone marrow transplantation2016
Autologous stem cell transplant for multiple myeloma patients 70 years or older.
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Pooled it
- Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.Haematologica · 2022Trial
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.Annals of hematology · 2019Trial
- Melphalan 140 mg/mHaematologica · 2018Trial
- Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.British journal of haematology · 2024Article
- Outcomes of melphalan 140 mg/mEJHaem · 2024Article
- The Effect of Age on High-Dose Therapy with Autologous Stem Cell Support in Multiple Myeloma: A Single-Center Experience.Journal of clinical medicine · 2024Article
- Personalized Treatment of Multiple Myeloma in Frail Patients.Current oncology reports · 2024Review
- Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation.Cancers · 2023Article
- Atrial Fibrillation and Cancer Patients: Mechanisms and Management.Current cardiology reports · 2022Review
- [Efficacy and safety of autologous hematopoietic stem cell transplantation in elderly multiple myeloma patients: a single center retrospective study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Long-term Effects of Regular Whole Blood Donation on Peripheral Blood CD34Iranian journal of pathology · 2022Article
- Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study).Frontiers in oncology · 2022Article
- Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.Haematologica · 2021Article
- Review
- Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).Bone marrow transplantation · 2021Article
- Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78.Bone marrow transplantation · 2021Article
- Melphalan 200 mg/mBone marrow transplantation · 2021Article
- Role of Stem Cell Transplantation in Multiple Myeloma.Cancers · 2021Review
- Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.Cancer treatment and research communications · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous stem cell transplant (Auto-SCT) is increasingly used in older patients with multiple myeloma (MM), despite lack of phase 3 trials in this age-defined population. For 207 consecutive MM patients who underwent Auto-SCT and were 70 years or older at transplant (study cohort), data were analyzed and compared with a younger cohort (1764 Auto-SCT patients <70 years old). The proportion of Auto-SCT in the older patients increased from 7.8% of all transplants in 1998-2006 to 12.9% in 2007-2015. Sixty percent of patients required stem cell mobilization with chemotherapy or plerixafor. Full-dose melphalan conditioning was given to 55% of the older patients compared with 93% of the younger patients (P<0.001). Older patients were more likely to be hospitalized (64% vs 55%; P=0.01), but hospitalization duration was comparable. For newly diagnosed patients, median PFS was 33.5 months for the older cohort and 33.8 months for the younger cohort (P=0.91), and median overall survival was 6.1 and 7.8 years, respectively (P=0.11). Presumably, a smaller fraction of patients, age 70-76, is selected for Auto-SCT, but the benefits are comparable to those seen for younger patients. Reduced-dose melphalan was given to approximately half the patients to avoid excessive toxicity.
Indexed as
Identifiers
27376447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.